Cargando…
A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy
describe a novel hybrid tumor-specific promoter, ARE-hTERT, composed of the human TERT gene promoter (hTERT) and the antioxidant response element (ARE) from the human GCLM gene promoter. The hybrid promoter retains the tumor specificity of the basal hTERT promoter but is characterized by an enhanced...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
A.I. Gordeyev
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762830/ https://www.ncbi.nlm.nih.gov/pubmed/29340219 |
_version_ | 1783291772770713600 |
---|---|
author | Kalinichenko, S. V. Shepelev, M. V. Vikhreva, P. N. Korobko, I. V. |
author_facet | Kalinichenko, S. V. Shepelev, M. V. Vikhreva, P. N. Korobko, I. V. |
author_sort | Kalinichenko, S. V. |
collection | PubMed |
description | describe a novel hybrid tumor-specific promoter, ARE-hTERT, composed of the human TERT gene promoter (hTERT) and the antioxidant response element (ARE) from the human GCLM gene promoter. The hybrid promoter retains the tumor specificity of the basal hTERT promoter but is characterized by an enhanced transcriptional activity in cancer cells with abnormal activation of the Nrf2 transcription factor and upon induction of oxidative stress. In the in vitro enzyme-prodrug cancer gene therapy scheme, ARE-hTERT promoter-driven expression of CD : UPRT (yeast cytosine deaminase : uracil phosphoribosyltransferase) chimeric protein induced a more pronounced death of cancer cells either upon treatment with 5-fluorouracil (5FC) alone or when 5FC was combined with chemotherapeutic drugs as compared to the hTERT promoter. The developed hybrid promoter can be considered a better alternative to the hTERT promoter in cancer gene therapy schemes. |
format | Online Article Text |
id | pubmed-5762830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | A.I. Gordeyev |
record_format | MEDLINE/PubMed |
spelling | pubmed-57628302018-01-16 A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy Kalinichenko, S. V. Shepelev, M. V. Vikhreva, P. N. Korobko, I. V. Acta Naturae Research Article describe a novel hybrid tumor-specific promoter, ARE-hTERT, composed of the human TERT gene promoter (hTERT) and the antioxidant response element (ARE) from the human GCLM gene promoter. The hybrid promoter retains the tumor specificity of the basal hTERT promoter but is characterized by an enhanced transcriptional activity in cancer cells with abnormal activation of the Nrf2 transcription factor and upon induction of oxidative stress. In the in vitro enzyme-prodrug cancer gene therapy scheme, ARE-hTERT promoter-driven expression of CD : UPRT (yeast cytosine deaminase : uracil phosphoribosyltransferase) chimeric protein induced a more pronounced death of cancer cells either upon treatment with 5-fluorouracil (5FC) alone or when 5FC was combined with chemotherapeutic drugs as compared to the hTERT promoter. The developed hybrid promoter can be considered a better alternative to the hTERT promoter in cancer gene therapy schemes. A.I. Gordeyev 2017 /pmc/articles/PMC5762830/ /pubmed/29340219 Text en Copyright ® 2017 Park-media Ltd. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kalinichenko, S. V. Shepelev, M. V. Vikhreva, P. N. Korobko, I. V. A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy |
title | A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy |
title_full | A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy |
title_fullStr | A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy |
title_full_unstemmed | A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy |
title_short | A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy |
title_sort | novel hybrid promoter are-htert for cancer gene therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762830/ https://www.ncbi.nlm.nih.gov/pubmed/29340219 |
work_keys_str_mv | AT kalinichenkosv anovelhybridpromoterarehtertforcancergenetherapy AT shepelevmv anovelhybridpromoterarehtertforcancergenetherapy AT vikhrevapn anovelhybridpromoterarehtertforcancergenetherapy AT korobkoiv anovelhybridpromoterarehtertforcancergenetherapy AT kalinichenkosv novelhybridpromoterarehtertforcancergenetherapy AT shepelevmv novelhybridpromoterarehtertforcancergenetherapy AT vikhrevapn novelhybridpromoterarehtertforcancergenetherapy AT korobkoiv novelhybridpromoterarehtertforcancergenetherapy |